The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 19, 2025

Filed:

Dec. 15, 2021
Applicant:

Hibercell, Inc., New York, NY (US);

Inventors:

William J. Grossman, Third Lake, IL (US);

Mary A. Antonysamy, Woodbury, MN (US);

Richard M. Walsh, Lino Lakes, MN (US);

Mariana I. Nelson, Rosemount, MN (US);

Nandita Bose, Plymouth, MN (US);

Michael E. Danielson, St. Paul, MN (US);

Kyle S. Michel, Eagan, MN (US);

Assignee:

HiberCell, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/716 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 16/12 (2006.01); C07K 16/14 (2006.01); G01N 33/50 (2006.01); G01N 33/554 (2006.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39583 (2013.01); A61K 31/716 (2013.01); A61K 39/39 (2013.01); A61K 39/39558 (2013.01); A61K 39/39575 (2013.01); A61K 45/06 (2013.01); A61K 47/6835 (2017.08); C07K 16/12 (2013.01); C07K 16/14 (2013.01); G01N 33/5047 (2013.01); G01N 33/554 (2013.01); G01N 33/56966 (2013.01); A61K 2039/55583 (2013.01); G01N 2400/24 (2013.01);
Abstract

This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.


Find Patent Forward Citations

Loading…